PC
EW icon

Palo Capital’s Edwards Lifesciences EW Stock Holding History

Palo Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,400
Closed -$378K – 157
2016
Q2 		$378K Buy
+11,400
New +$390K 0.13% 177

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Palo Capital's EW Position: Q3 2016 in Review

Palo Capital sold out of Edwards Lifesciences (EW) in Q3 2016, closing a stake of 11,400 shares — an estimated $378K sold.

Palo Capital first reported a position in EW in Q2 2016 and held it in 1 quarter. The position peaked at $378K in Q2 2016. 693 funds tracked by Wall St. Rank hold EW as of Q3 2016.

  • Palo Capital reported no remaining Edwards Lifesciences position as of Q3 2016 after selling out during the quarter.
  • Palo Capital sold 11,400 Edwards Lifesciences shares in Q3 2016, an estimated $378K.
  • Palo Capital first reported a position in Edwards Lifesciences in Q2 2016 and held it in 1 quarter.
  • Palo Capital's Edwards Lifesciences position peaked at $378K in Q2 2016.
  • 693 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2016.

Based on Palo Capital's 13F filing for Q3 2016, filed 20 Oct 2016.